Product Description
Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other|Oncology Unspecified|Colorectal Cancer|Lung Cancer
Phase 2: Insomnia|Depressive Disorder, Major|Dyspepsia|Enuresis|Oncology Unspecified|Overactive Bladder|Urinary Incontinence|Anesthesia Related|Fibromyalgia|Other|Spinal Cord Injuries
Phase 1: Healthy Volunteers|Kidney Diseases|Oncology Unspecified|Phobia, Social
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00891761 | P3 |
Withdrawn |
Lung Cancer |
2010-07-01 |
|
| NKV110721 | P3 |
Completed |
Colorectal Cancer |
2009-04-13 |
|
| 2007-005169-36 | P3 |
Completed |
Colorectal Cancer |
2009-04-07 |
|
| NKT102783 | P1 |
Completed |
Kidney Diseases |
2008-08-22 |